In support of an anti-tumor role for MMPs, treatment with the MMP inhibitor tanomastat, which has selective activity against MMP2, MMP3 and MMP9, was shown to lead to a worse outcome compared to standard treatments [106]. Here, MMP2 is linked to neoplasm.